long intergenic non-protein coding RNA 605Genealiases: []
Q-omics provides the consensus-scored LINC00605 profile across patient tissues and cancer cell-line models. LINC00605 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC00605 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, LINC00605 RNA expression shows 12,190 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, and KIRP as cancer lineages where LINC00605 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00605 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00605 survival associations across molecular data types. LINC00605 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00605 RNA expression–survival associations across cancer types. High LINC00605 expression shows unfavorable associations in UVM and LUAD, but favorable associations in KIRC, ACC, KICH and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC00605 RNA expression.
This table summarizes LINC00605 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00605. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00605 shows lower tumor expression in KIRP and THCA and higher tumor expression in COAD, BRCA, LUAD and STAD. The KIRP box plot shows higher LINC00605 RNA expression in normal versus tumor tissue (log2 FC = −0.654, t-test p = .004).
This table shows molecular features associated with LINC00605 in patient tissues and cancer cell lines. In patient samples, LINC00605 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
